Prevalence of human papillomavirus in head and neck cancer patients in India: a systematic review and meta-analysis

Human papillomavirus (HPV) is increasingly recognized as a significant risk factor in the development of head and neck cancers (HNCs), with varying prevalence and impact. This study aims to systematically review and analyze the prevalence of HPV in HNCs in India, providing insights into regional var...

Full description

Saved in:
Bibliographic Details
Published in:BMC infectious diseases Vol. 24; no. 1; p. 516
Main Authors: Satapathy, Prakasini, Khatib, Mahalaqua Nazli, Gaidhane, Shilpa, Zahiruddin, Quazi Syed, Serhan, Hashem Abu, Sharma, Rakesh Kumar, Sharma, Divya, Arora, Mithhil, Rustagi, Sarvesh, Na, AlKaabi, Alsayyah, Ahmed, Al-Hajeili, Marwan, Al-Subaie, Maha F, Alfaresi, Mubarak, Alissa, Mohammed, Rabaan, Ali A
Format: Journal Article
Language:English
Published: England BioMed Central Ltd 23-05-2024
BioMed Central
BMC
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Human papillomavirus (HPV) is increasingly recognized as a significant risk factor in the development of head and neck cancers (HNCs), with varying prevalence and impact. This study aims to systematically review and analyze the prevalence of HPV in HNCs in India, providing insights into regional variations. A comprehensive literature search was carried out using PubMed, Embase, and Web of Science up to November 10, 2023. Inclusion criteria focused on original research reporting HPV-positive cases among HNC patients in India. We used Nested-Knowledge software, for screening, and data extraction. The modified Newcastle-Ottawa Scale was used for quality assessment of included studies. We pooled the prevalence of HPV among HNC patients and performed a random-effects model meta-analysis using R software (version 4.3). The search yielded 33 studies, encompassing 4654 HNC patients. The pooled prevalence of HPV infection was found to be 33% (95% CI: 25.8-42.6), with notable heterogeneity (I² = 95%). Analysis of subgroups according to geographical location indicated varying prevalence rates. Specifically, the prevalence was 47% (95% CI: 32.2-62.4) in the eastern regions and 19.8% (95% CI: 10.8-33.4) in the western regions. No evidence of publication bias was detected. The observed considerable regional disparities on the prevalence of HPV in HNC patients in India emphasizes the need for integrated HPV vaccination and screening programs in public health strategies. The findings underline the necessity for further research to explore regional variations and treatment responses in HPV-associated HNCs, considering the impact of factors such as tobacco use and the potential benefits of HPV vaccination.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:1471-2334
1471-2334
DOI:10.1186/s12879-024-09357-2